Medical/Pharmaceuticals

ZEISS expands ophthalmic surgical workflows in Mexico with COFEPRIS approval for ARTEVO 850 and MICOR 700

* Elevates digital visualization for surgeons - ZEISS ARTEVO 850 surgical microscope provides ophthalmic surgeons in Mexico with advanced 3D visualization and end-to-end workflow integration. * Minimizes risk and increases O.R. efficiency for cataract surgery - ZEISS MICOR 700 first hand-held...

2026-05-13 21:00 2906

NYSE Content Update: Global Medical Response to Go Public After $479 Million IPO

NYSE issues a pre-market daily advisory direct from the trading floor. NEW YORK, May 13, 2026 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins...

2026-05-13 20:59 3993

Department of Health - Abu Dhabi and Fred Hutchinson Cancer Center collaborate on cancer research and personalized prevention

ABU DHABI, UAE, May 13, 2026 /PRNewswire/ -- The Department of Health - Abu Dhabi (DoH), regulator of the healthcare sector in the emirate, together with the Abu Dhabi Public Health Center (ADPHC), today announced the execution of a Memorandum of Understanding ("MOU") with Fred Hutchinson Cancer ...

2026-05-13 20:23 2966

High-Trend International Group Announces Pricing of $15 Million Registered Direct Offering with Global Institutional Investors

NEW YORK, May 13, 2026 /PRNewswire/ -- High-Trend International Group (NASDAQ: HTCO) ("HTCO" or the "Company"), a global ocean transportation company, today announced that it has entered into securities purchase agreements with global institutional investors for the purchase and sale of 2,307,700...

2026-05-13 20:00 3863

Synnovis and SOPHiA GENETICS Partner to Bring Blood-based Cancer Testing to Patients Across the U.K.

LONDON, May 13, 2026 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ: SOPH), a global leader in Ai-driven precision medicine, today announced a partnership with Synnovis, one of England's leading pathology providers, to bring liquid biopsy testing to lung and breast cancer patients across the U.K. as par...

2026-05-13 17:00 2596

Getting a leg up on diabetic lower limb amputation with new AI risk prediction model

SINGAPORE, May 13, 2026 /PRNewswire/ -- Personalised risk-based monitoring may soon be the norm for patients with diabetes at high risk of lower extremity amputation (LEA). Jointly developed by Singapore General Hospital (SGH), SingHealth, and the MOH Office for Healthcare Transformation (MOHT), ...

2026-05-13 16:55 2449

New Survey Reveals that Singaporeans Know More about Dementia But Nearly 7 in 10 are Unsure Where to Seek Help

Third national survey by SMU on dementia found that stigma persists; despite rising awareness, preparedness remains below neutral SINGAPORE, May 13, 2026 /PRNewswire/ -- Singaporeans are significantly more aware of dementia than they were five years ago, but most still do not know where to turn ...

2026-05-13 16:11 3135

THE ADECCO GROUP Q1 2026 RESULTS

Strong revenue growth, share gains and improved profitability, supported by rigorous execution ZURICH, Switzerland, May 13, 2026 /PRNewswire/ -- AD HOC ANNOUNCEMENT pursuant to Art. 53 Listing Rules of SIX Swiss Exchange HIGHLIGHTS * Accelerating organic revenue growth of +5.3% TDA yoy * Co...

2026-05-13 12:45 2546

New Nature Communications Publication Highlights Efsubaglutide Alfa's Effects on Glycaemia and β-Cell Function

HONG KONG, May 12, 2026 /PRNewswire/ -- A major new clinical study, SUPER 2, has been published in Nature Communications, reporting that Efsubaglutide Alfa, a long-actingGLP-1 receptor agonist, significantly improved glycaemic control in adults with type 2 diabetes inadequately controlled on metf...

2026-05-13 11:47 2977

WuXi Biologics Included in 2026 Dow Jones Best‑in‑Class World Index and Emerging Markets Index

SHANGHAI, May 12, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that, in recognition of its continued efforts and exceptional performance in advancing sustainability, the Company has been included i...

2026-05-13 11:33 2701

Innovent to Present Multiple Clinical and Preclinical Results of Mazdutide and Next-Generation Obesity & Metabolic Pipeline at the 2026 ADA Scientific Sessions

SAN FRANCISCO and SUZHOU, China, May 12, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune,...

2026-05-13 08:00 3143

Kelun-Biotech Receives Investigational New Drug Approval from CDE for SKB118, a PD-1 x VEGF Bispecific Antibody

CHENGDU, China, May 12, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced that it has received a clinical trial notice from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) appro...

2026-05-13 08:00 3248

GenScript Launches TurboCHO™ Protein Expression Kit, Delivering the Fastest Path to Antibodies in its Class

New kit offers researchers and development teams a meaningful advance in expression speed and output BOSTON, May 13, 2026 /PRNewswire/ -- GenScript Biotech Corporation

2026-05-13 00:19 3139

Porton Advanced and Dark Horse Consulting Group Announce Memorandum of Understanding Providing A Streamlined Path to Conducting IITs in China

CRANBURY, N.J. and SUZHOU, China, May 12, 2026 /PRNewswire/ -- Porton Advanced, a premier contract development and manufacturing organization (CDMO) specializing in Advanced Therapy Medicinal Products (ATMPs), and Dark Horse Consulting Group ("DHCG" or "the Group"), a leader in strategic and oper...

2026-05-12 23:00 4163

Isomorphic Labs secures $2.1 Billion funding to scale its AI drug design engine

Isomorphic Labs will use the funding to power its world-leading AI drug design engine, scale its business globally and progress its drug candidate pipeline. LONDON, May 12, 2026 /PRNewswire/ -- Isomorphic Labs, an AI-first drug design and development company, today announced it has raised $2.1 Bi...

2026-05-12 22:27 3147

Halia Therapeutics to Present Final Phase 2 Ofirnoflast Data in Lower-Risk MDS at EHA2026 and Announces Appointment of Han Myint, MD, FACP, as Chief Medical Officer

European Hematology Association (EHA) oral presentation to report 67% hematological improvement, durable transfusion independence, and no treatment-related serious adverse events in ESA-refractory lower-risk MDS Dr. Myint, a hematology leader and oncology drug-development executive, joins Halia ...

2026-05-12 20:39 3012

Insilico Medicine and Ribo Enter Strategic Collaboration Agreement: Leveraging AI Platform and Automated Lab for End-to-End Empowerment of RNA Interference and Oligonucleotide Therapeutics Development

SHANGHAI, May 12, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico", 03696.HK), a biotechnology company powered by generative artificial intelligence , today announced that the company has entered a strategic collaboration agreement with Suzhou Ribo Life Science Co., Ltd.  ("Ribo", 06938.HK), a ...

2026-05-12 20:30 3233

Ribo Announces Strategic Collaboration with Insilico Medicine to Accelerate siRNA Drug Development Driven by AI

SUZHOU, China, May 12, 2026 /PRNewswire/ -- Suzhou Ribo Life Science Co., Ltd. ("Ribo", 06938.HK) announced that the Company has entered into a strategic collaboration agreement with Insilico Medicine ("Insilico", 03696.HK). Both parties will leverage their respective core strengths in siRNA drug...

2026-05-12 20:30 3288

Avance Clinical Receives Frost & Sullivan's 2026 Global Company of the Year Recognition for Excellence in Biotech CRO Leadership

The company is recognized for its innovation, scientific expertise, and customer-centric clinical development model in the global biotechnology CRO market SAN ANTONIO, May 12, 2026 /PRNewswire/ -- Frost & Sullivan

2026-05-12 20:00 2278

New Data Show Gaps in Antiviral Pipeline Against High-Risk Viral Threats

Longitudinal analysis reveals clear gaps in global preparedness against emerging viral threats and future pandemics. CAMBRIDGE, Mass., May 12, 2026 /PRNewswire/ -- New global analysis of antiviral compounds released today has identified a critically thin pipeline of treatments in development tha...

2026-05-12 19:00 2064
12345678 ... 650